Literature DB >> 18985270

Attempted salvage resection for recurrent gastric or gastroesophageal cancer.

Brian Badgwell1, Janice N Cormier, Yan Xing, James Yao, Debashish Bose, Sunil Krishnan, Peter Pisters, Barry Feig, Paul Mansfield.   

Abstract

The purpose of this study was to determine the outcome of surgery for patients with recurrent gastric or gastroesophageal cancer. We queried records from 7,459 patients who presented with gastric or gastroesophageal cancer to our institution from 1973 through 2005 to identify those for whom resection of recurrent disease had been attempted. We assessed the associations between various clinicopathologic factors and resectability with logistic regression analysis and between clinicopathologic factors and overall survival (OS) with the Cox proportional hazards model. Sixty patients underwent attempted resection for recurrent cancer. In 31 cases (52%), recurrent disease proved unresectable at laparotomy. Factors associated with the ability to undergo re-resection included neoadjuvant treatment prior to initial resection [odds ratio (OR) 12.2, 95% confidence interval (CI) 1.9-75.6] and having an isolated local recurrence (OR 5.1, 95% CI 1.3-20.5). Of the 29 patients who underwent re-resection, 14 required adjacent organ resection, and 6 required interposition grafting. Three- and 5-year OS rates for all 60 patients were 21% and 12%, respectively; median follow-up time was 23 months. Median OS for patients undergoing resection was 25.8 months (95% CI 17.1-49.8) versus 6.0 months (95% CI 4.0-10.5) for unresectable patients (P < 0.001). Initial tumor location at the gastroesophageal junction was associated with diminished OS [hazard ratio (HR) 2.8, 95% CI 1.2-6.5] and ability to undergo resection of recurrence was associated with improved OS (HR 0.2, 95% CI 0.1-0.6). We conclude that surgical resection of select patients with recurrent gastric or gastroesophageal cancer can result in improved OS but often requires adjacent organ resection or interposition graft placement.

Entities:  

Mesh:

Year:  2008        PMID: 18985270     DOI: 10.1245/s10434-008-0210-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  7 in total

1.  Postoperative follow-up programs improve survival in curatively resected gastric and junctional cancer patients: a propensity score matched analysis.

Authors:  Leila Sisic; Moritz J Strowitzki; Susanne Blank; Henrik Nienhueser; Sara Dorr; Georg Martin Haag; Dirk Jäger; Katja Ott; Markus W Büchler; Alexis Ulrich; Thomas Schmidt
Journal:  Gastric Cancer       Date:  2017-07-24       Impact factor: 7.370

2.  Integration of radiotherapy and chemotherapy for abdominal lymph node recurrence in gastric cancer.

Authors:  J Lee; H I Yoon; S Y Rha; W J Hyung; Y C Lee; J S Lim; H S Kim; W S Koom
Journal:  Clin Transl Oncol       Date:  2017-05-05       Impact factor: 3.405

3.  [Current S3 guidelines on surgical treatment of gastric carcinoma].

Authors:  H-J Meyer; A H Hölscher; F Lordick; H Messmann; S Mönig; C Schumacher; M Stahl; H Wilke; M Möhler
Journal:  Chirurg       Date:  2012-01       Impact factor: 0.955

4.  Radiotherapy Combined with Chemotherapy for Regional Lymph Node Recurrence in Gastric Cancer.

Authors:  Liang Cai; Ganlu Ouyang; Xin Wang; Zhiping Li; Yali Shen
Journal:  Cancer Manag Res       Date:  2020-12-24       Impact factor: 3.989

5.  Preoperative Low Prealbumin Is Associated With Recurrence in Patients With Stage II/III Gastric Cancer After Laparoscopic D2 Gastrectomy.

Authors:  Chun Gao; Ci Dian Dan Zeng; Yi Xin Tong; Li Zhu; Sheng Zhang
Journal:  Front Surg       Date:  2022-04-01

6.  Successful curative surgery for postoperative oesophageal recurrence of oesophagogastric junction cancer.

Authors:  Masahiko Ikebe; Nobuhide Kubo; Seiichi Fukuyama; Tokujiro Yano
Journal:  BMJ Case Rep       Date:  2020-07-16

7.  SALVAGE SURGERY IN GASTRIC CANCER.

Authors:  Italo Beltrão Pereira Simões; Marina Alessandra Pereira; Marcus Fernando Kodama Pertille Ramos; Ulysses Ribeiro Junior; Bruno Zilberstein; Sergio Carlos Nahas; Andre Roncon Dias
Journal:  Arq Bras Cir Dig       Date:  2022-01-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.